RenewalBio is a biotechnology company focused on regenerative medicine. It utilizes its proprietary Stembroid™ platform to reprogram adult cells into induced pluripotent stem cells and guide their differentiation in a three-dimensional environment mimicking early embryonic development, generating transplantable cells and tissues matched to the patient's DNA. The technology aims to address the shortage of organ donors and immune rejection. Current efforts focus on developing hematopoietic stem cells for leukemia and immune disorders, with exploration into liver, heart, and pancreatic cell applications. The company is in the R&D stage, with participation limited to research collaborations and institutional partnerships.